Ligand Initiates Pivotal Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan in Patients with Multiple Myeloma
Ligand to Present Growth Prospects, Review Key Portfolio Assets and Introduce Financial Guidance at Analyst Day Event
Reminder: Ligand to Host Analyst Day on December 4th in New York City
Ligand Partner GlaxoSmithKline Receives FDA Approval for New Indication for PROMACTA® (eltrombopag)
Ligand Announces Positive Preclinical Data on HepDirect™ Liver-Targeted Antiviral for the Treatment of Hepatitis C
Ligand Pharmaceuticals Announces Second Quarter Results
Ligand to Report Second Quarter Results on August 8th
Ligand Partner GlaxoSmithKline Announces Priority Review for Supplemental New Drug Application for Promacta® for the Treatment of Thrombocytopenia in Adult Patients with Chronic Hepatitis C Infection
Ligand Licensee Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis™ (carfilzomib) for Injection
Ligand Partner Pfizer Announces European Medicines Agency Accepts Regulatory Submission for Bazedoxifene/Conjugated Estrogens for the Treatment of Symptoms Associated with Menopause and Osteoporosis
Ligand Announces New Presentation Time at the JMP Securities 7th Annual Healthcare Conference
Ligand to Present at the JMP Securities 7th Annual Healthcare Conference
Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association’s 72nd Scientific Sessions
Ligand Partner GlaxoSmithKline Submits US and European Regulatory Applications for use of PROMACTA/REVOLADE to Increase Platelet Counts in Patients with Hepatitis C
